US Tariff Threat Looms for Drugmakers
Sun Pharmaceutical Industries Ltd. saw its shares slide as much as 6% on Thursday, April 2. Reports indicate the Trump administration is preparing to announce tariffs on drugmakers. This potential move aims to compel companies into striking deals that guarantee lower prescription drug prices within the U.S.
Sun Pharma's Deep U.S. Market Exposure
The market's reaction stems from Sun Pharma's significant reliance on the U.S. market. For the fiscal year ending March 2025, U.S. sales for the Indian pharmaceutical giant climbed 5.8% to ₹16,200 crore, representing a substantial 31% of its total revenue. Growth in this key market was notably driven by the company's expanding specialty portfolio.
Sun Pharma's strategic shift toward innovation is a key driver of its U.S. performance. In FY25, about 20% of Sun Pharma's revenue came from its innovative medicines, up from 18% in FY24. Key products contributing to this include Illumya, Winlevi, Cequa, and Odomzo. The company also acquired Checkpoint Therapeutics in May 2025 to enhance its focus on novel cancer treatments.
Industry Scramble for Pricing Deals
Global pharmaceutical firms are actively pursuing agreements with the U.S. administration to mitigate these risks. Companies such as Pfizer Inc., AstraZeneca PLC, Johnson & Johnson, and Merck & Co. have already entered into multi-year tariff exemption agreements. These deals often involve pledges to expand U.S. operations or commit to new platforms like TrumpRx.gov.
Internal Perspective on Market Jitters
Despite market jitters, sources within Sun Pharma have reportedly indicated to CNBC-TV18 that they do not anticipate a significant impact on their operations. However, shares of the company remained among the top decliners on the Nifty 50 index, trading lower at ₹1,662.6.